Percutaneous Ethanol and Acetic Acid Ablation of Hepatocellular Carcinoma
| Autor: | Vibhu Kapoor, F. Leland Thaete |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Hepatitis B virus
medicine.medical_specialty education.field_of_study Cirrhosis Transmission (medicine) business.industry Hepatitis C virus medicine.medical_treatment Population medicine.disease_cause medicine.disease Gastroenterology digestive system diseases Internal medicine Hepatocellular carcinoma medicine Percutaneous ethanol injection education Transcatheter arterial chemoembolization business |
| Zdroj: | Current Clinical Oncology ISBN: 9781588291257 |
| DOI: | 10.1007/978-1-59259-844-1_7 |
| Popis: | Hepatocellular carcinoma (HCC) is the most common primary hepatic tumor. Globally, HCC is one of the most common malignant visceral tumors (1,2), with more than 350,000 cases reported every year (1). Annual incidence rate in North and South America for HCC is 2–4 cases per 100,000 persons (1). The worldwide distribution of HCC is closely linked to the prevalence of hepatitis B infection. There is a 200-fold increased risk of HCC in adults who become hepatitis B virus (HBV) carriers during infancy as a result of vertical transmission from the infected mother (3). HCC in this population frequently occurs without coincident cirrhosis (in approx 50% cases) and at a younger age—often between 20 and 40 years (1). In contrast, cirrhosis is present in 85–90% cases of HCC in the Western population (low-incidence region), where HBV is not prevalent. The most common associations with HCC in this region are alcohol and chronic infection with hepatitis C virus (HCV) (1); rarely does it occur before age 60 years (1). Males outnumber females in the distribution of HCC in both the high- and low-incidence regions; the male/female ratio is 8:1 in the high-incidence population and 2:1 to 3:1 in the low-incidence population (1,2). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|